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Open access under CC Various inﬂammatory stimuli that activate the nuclear factor kappa B (NF-jB) signaling pathway converge
ona serine/threoninekinase thatdisplays akey role in theactivationofNF-jB: the I kappaBkinaseb (IKK-b).
Therefore, IKK-b is consideredan interesting target for combating inﬂammationandcancer. Inour study,we
developed a ligand-based pharmacophoremodel for IKK-b inhibitors. Thismodelwas employed to virtually
screen commercial databases, giving a focused hit list of candidates. Subsequently, we scored bymolecular
shape to rank and further prioritized virtual hits by three-dimensional shape-based alignment. One out of
ten acquired and biologically tested compounds showed inhibitory activity in the lowmicromolar range on
IKK-b enzymatic activity in vitro and on NF-jB transactivation in intact cells. Compound 8 (2-(1-adaman-
tyl)ethyl 4-[(2,5-dihydroxyphenyl)methylamino]benzoate) represents a novel chemical class of IKK-b
inhibitors and shows that the presented model is a valid approach for identiﬁcation and development of
new IKK-b ligands.
 2010 Elsevier Ltd. Open access under CC BY-NC-ND license.Activation of the nuclear factor kappa B (NF-jB) signaling
pathway by various stimuli, of which tumor necrosis factor-a
(TNF-a) is probably the most extensively studied, induces the tran-
scription of proinﬂammatory target genes via the activation of a
complex intracellular signaling cascade, involving among others
TNF receptor-associated factors (TRAFs) 2, 5, and 6, I kappa B kinases
(IKKs), and inhibitoryjBproteins (IjB). The substantial role of I kap-
pa B kinase b (IKK-b) in NF-jB signaling has been shown by evaluat-
ing small molecule IKK-b inhibitors in preclinical models.1,2 The
expression of proinﬂammatory molecules that may promote tumor
growth is also facilitated by the IKK/NF-jB signaling pathway.3 IKK-
b forming the IKK complex together with IKK-a and the regulatory
domain NEMO (IKK-c) is predominantly contributing to the phos-
phorylation of the inhibitor of NF-jB protein, IjB-a, at residues
Ser32 and Ser36.4 This results in the proteasomal degradation ofer@zedat.fu-berlin.de
ada University, Sekip Utara,
BY-NC-ND license.IjB-a and the release of NF-jB from IjB-a. As inhibition of IKK-b
is abolishing NF-jB activation, the development of small molecule
IKK-b inhibitors as potential anti-inﬂammatory and chemosensitiz-
ing agents is promising.5–8
In virtual screening large databases of drug-like molecules are
ﬁltered in a knowledge-driven approach to prioritize compounds
for biological testing. The use of an X-ray structure or a model of
the target receptor to predict the binding mode and the binding
afﬁnity by means of high-throughput docking is well established.9
Previous studies on IKK-b inhibitors employed molecular docking
of compound libraries into the active site of homology models to
investigate binding modes of inhibitors10 and eventually prioritize
candidates from a pharmacophore-based screening hitlist for a bio-
logical evaluation.11 However, as stated by Muegge, the use of a
homology model of the target receptor for the docking campaign
in situations, where an X-ray crystal structure is not available, adds
a considerable amount of uncertainty to the predictions, accounting
that the macromolecule conformation employed in the docking
experiment is a predicted conformation, which has to be regarded
as putative.12 In our study, we therefore deliberately focused on
ligand-based virtual screening techniques to identify novel
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Figure 1. Overview of the molecular modeling workﬂow.
Figure 3. Conﬁrmed biologically inactive compounds 6 and 7.20,21
578 S. M. Noha et al. / Bioorg. Med. Chem. Lett. 21 (2011) 577–583compounds with activity for IKK-b. We started the development of
ligand-based pharmacophore models based on training set
compounds with high activity (IC50 <100 nM) and several-fold
selectivity for IKK-b over IKK-a. Afterward, the model was carefully
and iteratively reﬁned with exclusion volume spheres (XVOLs) and
shape constraints. The ﬁnal model was used to virtually screen the
database from the National Cancer Institute (NCI). For post-ﬁlter-
ing, the OMEGA/ROCS13,14 software packages from OpenEye
(www.eyesopen.com) were employed to re-score the NCI hitlistFigure 2. Heterogeneous datasby comparing the querymolecules (NCI hits) with two highly active
and structurally diverse IKK-b inhibitors as reference molecules. In
ROCS, a different alignment algorithm accounting shape/physico-
chemical properties for the query molecule orientation gives a
complementary ﬁlter for the hitlist from pharmacophore-based
screening. Figure 1 shows a graphical summary of the workﬂow.
In order to implement this modeling work-ﬂow, a dataset of
128 active and 44 biologically conﬁrmed inactive compounds
was collected from the literature.15–31 It is well-known that kinase
inhibitors tend to form hydrogen-bonds to the hinge region, which
is a highly conserved segment among protein kinases.32 Therefore,
the IKK-b inhibitors are also supposed to interact with the hinge
motif, which in case of IKK-b is composed of Glu97 and Cys99, to
stabilize inhibitor binding and contribute to the reduction of cata-
lytic enzyme activity.10,11 The heterogeneous dataset of IKK-b
inhibitors is in all cases composed of chemical moieties to formet of IKK-b inhibitors.15–19
Figure 4. Ligand-based pharmacophore model for IKK-b inhibitors. The model consists of ﬁve features, two HBDs, one HBA, one RA, and one H feature. Chemical features are
color-coded: HBD—magenta, HBA—green, H—cyan, aromatic ring—brown, shape—shaded volume, XVOL—gray (left). Compound 8 ﬁtted into the model (right).
Table 1
Training set for HipHop reﬁne model
Compound Activity [IC50] Class Reference
1 0.4 nM Highly active 15
2 2 nM Highly active 16
3 3 nM Highly active 17
4 13 nM Highly active 18
6 30 lM Inactive 20
7 >20 lM Inactive 21
Figure 5. Compounds 2 and 5 were selected as reference molecules for the shape-
based scoring. Shown is the 3D illustration of compounds 2 (a) and 5 (b) with
solvent accessible surface.
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ring and a hydrophobic moiety in most cases (Fig. 2).
For pharmacophore model generation conformational models of
the training set compounds were generated with a maximum num-
berof 255conformationspermoleculeand ‘BEST’ qualitywithinDis-
coveryStudio 2.1. The ‘HipHop algorithm’ of Catalyst 4.11 from
Accelrys (accelrys.com), which now is incorporated into Discovery-
Studio, was used to build the common feature hypotheses.33 The re-
sults from experiments with different training sets showed that the
four training set compounds 1, 2, 3, and 4 (Fig. 2) aremost appropri-
ate for ligand-based pharmacophore generation. Pharmacophore
model generation based on these highly active molecules resulted
in ten ﬁve-feature hypotheses. Out of these models, the highest
ranked 3D pharmacophore displayed the best results in an initial
model validationandwas selected for a step-wisemodel reﬁnement.
The ‘Reﬁne algorithm’—in DiscoveryStudio available as ‘Steric
reﬁnement with excluded volumes’ protocol—was used to strategi-
cally place XVOLs in approximated ‘forbidden areas’ from steric hin-
drance around the ligand-basedmodel.34 This reﬁnementwas based
on information from conﬁrmed biologically inactive compounds 6
and 7 (Fig. 3). The ﬁnal model (Fig. 4) consisted of two hydrogen-
bonddonor (HBD), onehydrogen-bondacceptor (HBA), one ringaro-
matic (RA), and one hydrophobic feature (H), respectively. In model
reﬁnement, XVOLs and a molecular shape constraint derived fromTable 2
Results from the theoretical model validation by screening the literature dataset and the
Literature dataset
Active compounds Conﬁrmed
Hypo1 34 6
(27.4%) (13.6%)
Hypo1-R1 33 1
(26.6%) (2.3%)
Hypo1-R1-S1 31 0
(25.0%) (0.0%)the highly active compound 1 in its conformation that optimally ﬁt
thehighest rankedmodelwereaddedas steric restrictions. The com-
plete training set of our HipHop reﬁne model is shown in Table 1.
Due to the availability of only 44 conﬁrmed biologically inactive
compounds on IKK-b, a diverse virtual library consisting of 12,775
diverse random compounds (‘decoy set’) was generated using the
program ilib diverse35–37 for model validation. For the theoretical
assessment of predictability, active literature dataset compounds
that were not included in the training set and the virtual decoy
database were combined to a validation dataset. The enrichment
of active compounds in the resulting hit lists was evaluated by cal-
culating enrichment factors (EF) using the equation
EF ¼ TP=n
A=Nvirtual library decoys
Virtual library decoys EF
inactives
191 15.7
(1.5%)
115 23.2
(0.9%)
94 25.8
(0.7%)
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Figure 6. Compounds selected for biological evaluation.
580 S. M. Noha et al. / Bioorg. Med. Chem. Lett. 21 (2011) 577–583where TP is the number of active compounds ﬁtting into the model,
n is the total number of molecules (active compounds and decoys)
that were returned as hits by the pharmacophore-based screening,
A is the number of active compounds in the entire validation data-
base, and N is the number of all compounds in the validation
database.38
The training set composed of the highly active compounds 1–4
resulted in ten pharmacophore models, where the 1st-ranked
model showed the best enrichment rate. This model was iteratively
reﬁned by addition of XVOLs and shape constraints, which im-
proved the prediction quality from an initial enrichment factor of
15.7–25.8 in the ﬁnal model (see Table 2 for enrichment factors
and percentage of actives, inactives and decoys identiﬁed).
3D resulting pharmacophore model ‘Hypo-1-R1-S1’ was used to
screen the compound database of the National Cancer Institute
(NCI) for new compounds that fulﬁll the required chemicalfeatures and steric constraints. First, conformers for all NCI com-
pounds were generated using a maximum of 100 conformations
per molecule and the Discovery Studio ‘FAST’ algorithm. Virtual
screening was conducted using the ‘fast ﬂexible search’ method
and 1860 compounds out of 247,041 entries (0.8%).
In order to select the most promising compounds from the large
number of hits, the pharmacophore hit list was ranked using
shape-based scoring employing ROCS—Rapid Overlay of Chemical
Structures. The algorithm is based on the idea that the molecular
shape of compounds is similar if the molecules overlay well and
any volume mismatch is resulting from shape dissimilarity. For
the superimposition of molecules, a smooth Gaussian function is
used to represent the molecular volume. Subsequently, the overlay
of the molecules is corrected by simple matching of chemical func-
tionalities.39 A recent study40 shows that the enrichment of shape-
based screening does not necessarily depend on the availability of
Figure 7. Alignment of the biologically active compound 8 (green) to the ROCS
query molecule compound 5 (blue).
Figure 8. IKK-b inhibitory activity of the compound identiﬁed by the virtual
screening approach. IKK-b activity is determined by ELISA as described in detail in
the experimental section. The enzymatic activity of human recombinant IKK-b is
quantiﬁed for 30 min at 30 C in the presence of DMSO vehicle, different
concentrations of 8, or 1 lM IKK-b inhibitor IV that was used as a control. The
color development of the substrate was quantiﬁed on a GeniosPro plate reader
(Tecan, Austria), and the IKK-b activity is presented as percentage of the activity of
the vehicle treated control. The graph represents the mean of three independent
experiments ± SD (*p <0.05 **p <0.01 and ***p <0.001, two-tailed paired t-test).
Figure 9. HEK293 cells stably transfected with a NF-jB luciferase reporter were
treated as indicated and stimulated with 2 ng/ml TNF-a for 6 h before cell lysates
were subjected to detection of luciferase activity. The data shown are means ± SD
from three independent experiments. (**p <0.01 and ***p <0.001, two-tailed paired
t-test).
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encouraged us to employ this complementary technique as a
post-processing of the retrieved NCI hit list.
The 3D similarity-based ranking with ROCS was performed
using a combined scoring method, using the shape Tanimoto coef-
ﬁcient and the score retrieved from the ROCS ‘color force ﬁeld’,
which includes rough information about chemical functions. As
both scores can vary between 0 and 1, the combo score as the
sum of both varies between 0 and 2.34 For the shape-based
screening we selected compounds 2 and 5 from the literaturedataset—two structural dissimilar and highly active reference mol-
ecules (Figs. 2 and 5). The reference molecules were submitted to
3D geometry generation using CORINA41 fromMolecular Networks
(www.molecular-networks.com). The option for conformational
sampling of ring moieties was enabled, giving ten conformations
for each reference molecule. The conformational models of the
different query molecules were calculated using OMEGA (default
settings, with a maximum of 400 conformations per molecule).
In the subsequently carried out shape-based similarity screening,
the query molecules were ranked using the combo score. We
accounted the highest similarity score for each query molecule,
which was retrieved from virtually screening the ensemble of
conformations for each reference molecule against all single query
molecule conformations. This highest scoring conformation was
determined using the multi-conformer query option in ROCS. The
re-scored hit list was visually inspected and ten compounds were
chosen for biological testing (Fig. 6). Compounds with a high score
were preferred in the selection. However, we emphasized on com-
pounds, which were (i) available at the time of our study, and (ii)
showed sufﬁcient structural diversity among each other.
Out of these ten virtual screening hits, compound NSC 719177
(compound 8, Figs. 4, 6 and 7), showed inhibitory activity against
IKK-b in a cell-free in vitro assay42 with an IC50 of 6.95 ± 0.55 lM
(Fig. 8).
In order to verify the effectiveness of 8 in intact cells, we tested
its ability to block NF-jB activation induced by TNF-a in stably
transfected HEK293 cells carrying a luciferase reporter gene driven
by a promoter containing multiple copies of the NF-jB response
element.43 Similar to the control IKK-b inhibitor (IKK-b inhibitor
IV),44 compound 8 inhibited TNF-a-induced luciferase activity
dose-dependently. The inhibitory effect (IC50: 5.85 ± 0.97 lM,
Fig. 9) appeared in a concentration range similar to that needed
for the inhibition of IKK-b enzyme activity in vitro.
In order to get hints about possible binding modes of compound
8, it was submitted to molecular docking using a homology model
of IKK-b.45 The docking results suggest a contact of the inhibitor
with the hinge region by forming a hydrogen bond between
Cys99 and the ester carbonyl group of the ligand. Additionally,
two hydrogen bonds can be surmised with the residue Asp166
by one phenolic hydroxyl group and by the amine in the linker
Figure 10. Predicted binding pose of compound 8 docked into a homology model of IKK-b. The 3D representation of the ligand binding pose is shown with the receptor-
binding surface (color-coded by aggregated hydrophilicity/hydrophobicity: blue/gray, respectively). In the 2D representation predicted protein–ligand interactions are given.
Chemical features are color-coded: red/green arrow—hydrogen-bond acceptor/donor; yellow spheres—hydrophobic interactions.
582 S. M. Noha et al. / Bioorg. Med. Chem. Lett. 21 (2011) 577–583chain. The two aromatic moieties of the ligand are positioned in
hydrophobic pockets of the assumed binding site (Fig. 10).
In brief, we report the development of a ligand-based pharma-
cophore model for IKK-b inhibitors, as well as the application of
pharmacophore-based virtual screening techniques combined
with 3D shape-based re-scoring. Biological testing of 10 virtual
screening hits resulted in the identiﬁcation of compound 8, which
has inhibitory activity in the low micromolar range, both in a cell-
free IKK-b in vitro assay and a cell-based NF-jB transactivation as-
say. Therefore, compound 8 is a promising candidate for further
medicinal chemistry optimization in order to obtain novel drugs
against inﬂammation and cancer.
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